Placebo Responses in Neurologic Clinical Trials, an Issue of Neurologic Clinics

Volume 44-1
Erscheinungsjahr 2026
ISBN: 978-0-443-31326-4
Verlag: Elsevier Health Sciences

Buch, Englisch, 240 Seiten, Format (B × H): 152 mm x 229 mm

In this issue of Neurologic Clinics, guest editors Drs. Aziz Shaibani and Fabrizio Benedetti bring their considerable expertise to the topic of Placebo Responses in Neurologic Clinical Trials. Top experts discuss the placebo response (not just the placebo effect) across a variety of neurologic clinical trials, providing an important overview of the occurrence and magnitude of the placebo response in different neurologic disorders. This issue offers key information for clinical trials in neurology as well as for clinical practice. - Contains 12 relevant, practice-oriented topics including definitions of placebo effect and placebo response; placebo responses in clinical trials of anti-migraine drugs; placebo responses in trials of Parkinson’s disease; placebo responses in clinical trials of epilepsy; placebo responses in trials for multiple sclerosis; Harnessing the placebo effect in clinical practice; and more
- Provides in-depth clinical reviews on placebo responses in neurologic clinical trials, offering actionable insights for clinical practice
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews

Autoren/Hrsg.

Shaibani, Aziz

Benedetti, Fabrizio

Fachgebiete

• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft

Über Autor(innen)

Benedetti, Fabrizio
Prof. Fabrizio Benedetti, MD is Professor of Neurophysiology and Human Physiology at the University of Turin Medical School, Italy, and Director of Medicine and Physiology of Hypoxia at Plateau Rosà, Switzerland. He identified the basic mechanisms of placebo and nocebo effects across a number of medical conditions and therapeutic interventions, including pain, Parkinson's disease, the endocrine system and oxygen-dependent critical life functions. He has been a consultant and advisor at NIH, NIMH, NIDA, NCCAM and at Harvard University since 2000. He is recipient of the 2009 Medical Book Award of the BMA, the 2012 Seymour Solomon Award of the American Headache Society, and the 2015 William S Kroger Award of Behavioral Medicine from the American Society of Clinical Hypnosis. In 2023 he received the Lifetime Achievement Award of the Society for Interdisciplinary Placebo Studies. He is currently on the editorial boards for Current Neuropharmacology and Canadian Jrnl of Pain.